Google
NAMS — NEWAMSTERDAM PHARMA COMPANY N.V. ORDINARY SHARES (Healthcare >> Biotechnology)
NAMS FAQ
What is NAMS's ROE?
NEWAMSTERDAM PHARMA COMPANY N.V. ORDINARY SHARES reports a Return on Equity (ROE) of -31.98%.
What is NAMS's dividend yield?
NEWAMSTERDAM PHARMA COMPANY N.V. ORDINARY SHARES offers a dividend yield of 0.00%.
What is NAMS's Deepscope Quality Score?
Deepscope rates NAMS's overall financial quality at 54 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy NAMS?
Deepscope's AI Timing Score for NAMS is 55 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does NAMS belong to?
NEWAMSTERDAM PHARMA COMPANY N.V. ORDINARY SHARES is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 32.67
Price
0.56
(1.74%)
Day Change
|
|
|---|
NAMS, the overall quality is not quite good ( Quality = 54) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Net profit margin is relatively low.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 32.67 |
| PBV / Sector |
5.64 / 4.58
|
| Earning Per Share | -1.85 |
| PE / Sector |
N/A / 17.10
|
| PEG or PE/Growth / Sector |
N/A / 0.52
|
| Average 1M Daily Value |
57.88 M
|
| Average 1W Daily Value |
46.34 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
37% |
| Ability to Make Profit |
|
60% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-05 09:11:53 |
| Symbol | NAMS |
| Name | NEWAMSTERDAM PHARMA COMPANY N.V. ORDINARY SHARES |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 116.90 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 3,753.79 / 8,655.90 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Gooimeer 2-35, Naarden, Netherlands, 1411 DC
Phone: 31 35 206 2971
Website: https://www.newamsterdampharma.com
Employees: 100
Sector: Healthcare >> Biotechnology
Description: NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
